Cellular therapy for ocular degeneration
First Claim
1. A method of treating a patient having an ocular degenerative condition, the method comprising administering to the patient mesenchymal stem cells in an amount effective to treat the ocular degenerative condition, wherein the mesenchymal stem cells are characterized by the expression of at least one of the following surface markers:
- CD29, CD44, CD105 or CD166, and the lack of expression of at least one of CD14, CD34 or CD45.
3 Assignments
0 Petitions
Accused Products
Abstract
Compositions and methods applicable to cell-based or regenerative therapy for ophthalmic diseases and disorders comprising mesenchymal stem cells, particularly those characterized by the expression of at least one of the following surface markers: CD29, CD44, CD105 or CD166, and the lack of expression of at least one of CD14, CD34 or CD45.
-
Citations
31 Claims
-
1. A method of treating a patient having an ocular degenerative condition, the method comprising administering to the patient mesenchymal stem cells in an amount effective to treat the ocular degenerative condition, wherein the mesenchymal stem cells are characterized by the expression of at least one of the following surface markers:
- CD29, CD44, CD105 or CD166, and the lack of expression of at least one of CD14, CD34 or CD45.
- View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16)
- 17. A pharmaceutical composition for treating a patient having an ocular degenerative condition, the composition comprising mesenchymal stem cells in an amount effective to treat the ocular degenerative condition, and a pharmaceutically acceptable carrier.
Specification